See our Annual Report for the year 2025 for detailed updates on our pipeline candidates.

Pipeline

Breakthrough technologies to revolutionize medicine

25 + Phase 2 and phase 3 clinical trials in oncology

Explore late-stage clinical trials

10 + Novel-novel combination trials

Explore combination trials

€ 2.10 bn Investment into R&D in 2025 to address cancer care across indications with high incidence

Explore our diversified pipeline

Stay up to date

Sign up for our email alert for news on our growing pipeline